There has been a recent acceleration in clinical research of possible pharmacological therapies for DMD, including studies aimed at restoring dystrophin in skeletal muscle, and disease-modifying agents targeting inflammation and other pathogenic aspects of the disease. Here, DMD is linked to Duchenne muscular dystrophy.